Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agensys has begun the first phase I clinical trial of its investigational antibody AGS-PSCA in patients with advanced prostate cancer.
Subscribe to our email newsletter
AGS-PSCA is a fully human monoclonal antibody directed to Agensys’ proprietary target prostate stem cell antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with all stages of prostate, pancreatic and bladder cancers.
Agensys and Merck recently announced the formation of a global alliance to jointly develop and commercialize the compound.
The phase I, dose-escalation trial is being conducted at both Memorial Sloan-Kettering Cancer Center and Johns Hopkins Kimmel Cancer Center. The trial is designed to evaluate the safety and pharmacokinetic profile of a multiple-dose regimen of AGS-PSCA. Up to 24 patients with hormone refractory prostate cancer will be enrolled.
“Based on preclinical efficacy and safety results, AGS-PSCA has the potential to provide a much-needed targeted therapy for patients with prostate, pancreatic and bladder cancers,” said Dr Aya Jakobovits, senior vice president, Technology and Corporate Development and chief scientific officer.